A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus

Barchart
Barchartで開く
A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus

Eli Lilly (LLY) shares opened higher on Nov. 16 after the pharmaceutical behemoth announced an agreement to acquire biotechnology company Calytrix Bio for up to $1.5 billion. The transaction will add a promising rare blood disorder program to LLY’s pipeline and underscores its willingness to deploy capital beyond its blockbuster obesity and diabetes franchises. 

At the time of writing, Eli Lilly stock is up about 33% versus the start of this year. 

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

www.barchart.com

Why Calytrix Deal Matters for Eli Lilly Stock

The acquisition gives Lilly access to Calytrix’s lead asset, a biparatopic antibody targeting mutant calreticulin (mCALR)-driven essential thrombocythemia and myelofibrosis — two serious blood disorders with significant unmet need.

For shareholders, the transaction is notable because it brings another potentially high-value program under LLY’s umbrella and diversifies its revenue stream beyond its core cardiometabolic business.

The deal reinforces management’s commitment to broadening the pipeline across multiple therapeutic areas, instead of relying exclusively on products such as Mounjaro, Zepbound, and Foundayo.

If Calytrix’s lead candidate advances successfully through development, it could open a massive new opportunity for Eli Lilly in hematology while reinforcing its reputation as one of the industry’s most aggressive dealmakers. 

Are LLY Shares a Good Long-Term Investment?

Eli Lilly’s recent financials warrant owning its shares for the long term as well. In Q3, the company recorded $24.4 billion in revenue on $7.48 per share of earnings — both ahead of Street estimates — and raised its full-year guidance as well. 

Meanwhile, the strength of LLY’s balance sheet positions it well to sustain its dividend yield, which currently sits at 0.48%, making the pharma stock even more attractive as a long-term holding. 

Investors should also note that Eli Lilly shares have a history of gaining over 3.5% on average in December, a seasonal pattern that improves its near-term appeal as well. 

How Wall Street Recommends Playing Eli Lilly

Wall Street analysts also remain convinced that LLY stock is not out of steam just yet. 

According to Barchart, the consensus rating on Eli Lilly sits at “Strong Buy,” with price targets as high as $1,700 indicating significant further upside potential from current levels.  

www.barchart.com
On the date of publication, Wajeeh Khan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Michael Burry Is Betting on an AI Stock Selloff. I’d Rather Buy the Dip. CoreWeave CEO Michael Intrator Just Canceled His 10b5-1 Trading Plan. What That Means for CRWV Stock. A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus Shorting ConocoPhillips Puts and Put Credit Spreads Are Attractive Income Plays